Comparative Study of the Effect of Growth Hormone on Left Ventricular Ejection Fraction and Thickness among Patients Suffering from Ischemic Heart Failure: A Randomized Double-Blinded Clinical Trial Study

Document Type : Original Article (s)

Authors

1 Associate Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Cardiologist, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 General Practitioner, Heart Failure Research Center AND Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Based on the previous studies, stem cells have been proved to be activated within 4 weeks after myocardial infarction (MI) by growth hormone (GH). In this study, we aimed to assess the relation of 3 months of GH prescription on left ventricular ejection fraction (LVEF), and thickness of interventricular septum (IVS) and posterior left ventricle (LV) among Iranian individuals suffering from heart failure because of their first MI attack.Methods: 16 clinically stable patients with history of MI suffering from heart failure with LVEF < 40% were eligible for enrollment in this randomized clinical trial study. They were randomly assigned to groups receiving 5 mg subcutaneous GH (n = 8) or placebo (n = 8) with injections done each other day for 3 months. Cardiac outcomes including LVEF, and thickness of IVS and posterior LV were assessed at the end of the intervention.Findings: LVEF was remarkably increased by three months started from baseline of 32 ± 3.80 percent in patients receiving GH to 43.80 ± 4.60 percent (P = 0.002). Moreover, LVEF was significantly higher in participants receiving GH (43.80 ± 4.60 percent) compared with placebo group (33.14 ± 4.84 percent) at the end of trial (P = 0.003). IVS or posterior LV wall thickness failed to prove any considerable associations in GH or placebo groups.Conclusion: Our outcomes revealed that GH administration was associated with raised LVEF function among the patients with heart failure due to MI attack.

Keywords

References

  1. McMurray JJ, Stewart S. The burden of heart failure. Eur Heart J Suppl 2002; 4(Supplement D): D50-D58.
  2. Lam CSP. Heart failure in Southeast Asia: Facts and numbers. ESC Heart Fail 2015; 2(2): 46-9.
  3. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113(6): 646-59.
  4. Chong AY, Rajaratnam R, Hussein NR, Lip GY. Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. Eur J Heart Fail 2003; 5(4): 569-74.
  5. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19(11): 1704-11.
  6. Isgaard J, Bergh CH. Clinical potential of growth hormone in the treatment of congestive heart failure. BioDrugs 1999; 12(4): 245-50.
  7. Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K, et al. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res 1999; 43(1): 157-64.
  8. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di GA, Serpico R, et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003; 41(12): 2154-63.
  9. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110(24): 3674-9.
  10. Fazio S, Palmieri EA, Affuso F, Cittadini A, Castellano G, Russo T, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007; 92(11): 4218-23.
  11. Napoli R, Guardasole V, Matarazzo M, Palmieri EA, Oliviero U, Fazio S, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39(1): 90-5.
  12. Bocchi E, Moura L, Guimaraes G, Conceicao Souza GE, Ramires JA. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol 2006; 110(3): 313-7.
  13. Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: An update on a topic at heart. Endocrine 2015; 48(1): 25-35.
  14. Smit JW, Janssen YJ, Lamb HJ, van der Wall EE, Stokkel MP, Viergever E, et al. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab 2001; 86(10): 4638-43.
  15. Gu X, Xie Y, Gu J, Sun L, He S, Xu R, et al. Repeated intracoronary infusion of peripheral blood stem cells with G-CSF in patients with refractory ischemic heart failure--a pilot study. Circ J 2011; 75(4): 955-63.
  16. Le CP, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J Clin Endocrinol Metab 2007; 92(1): 180-5.
  17. Osterziel KJ, Blum WF, Strohm O, Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab 2000; 85(4): 1533-9.
  18. Acevedo M, Corbalan R, Chamorro G, Jalil J, Nazzal C, Campusano C, et al. Administration of growth hormone to patients with advanced cardiac heart failure: Effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003; 87(2-3): 185-91.
  19. Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol 1999; 84(4): 430-3.
  20. Isgaard J, Carlsson L, Isaksson OG, Jansson JO. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 1988; 123(6): 2605-10.
Journal of Isfahan Medical School
Volume 37, Issue 536 - Serial Number 536
May and June 2019
Pages 869-875

Files

History

  • Receive Date: 13 July 2019
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics